Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cytomegalovirus Infections | 8 | 2022 | 35 | 4.190 |
Why?
|
| Kidney Transplantation | 8 | 2022 | 120 | 3.520 |
Why?
|
| Organ Transplantation | 4 | 2022 | 30 | 1.730 |
Why?
|
| Anti-Infective Agents | 2 | 2022 | 36 | 1.620 |
Why?
|
| Cytomegalovirus | 5 | 2022 | 15 | 1.590 |
Why?
|
| Graft Rejection | 6 | 2017 | 63 | 1.530 |
Why?
|
| Transplant Recipients | 6 | 2022 | 21 | 1.360 |
Why?
|
| Opportunistic Infections | 2 | 2017 | 7 | 1.070 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2022 | 115 | 1.050 |
Why?
|
| Cell-Free Nucleic Acids | 2 | 2022 | 12 | 1.020 |
Why?
|
| Patient Readmission | 3 | 2015 | 128 | 0.990 |
Why?
|
| Retrospective Studies | 14 | 2022 | 3367 | 0.940 |
Why?
|
| Daptomycin | 1 | 2022 | 4 | 0.830 |
Why?
|
| Antimicrobial Stewardship | 1 | 2022 | 9 | 0.830 |
Why?
|
| Antiviral Agents | 3 | 2022 | 69 | 0.820 |
Why?
|
| Staphylococcal Infections | 2 | 2016 | 150 | 0.800 |
Why?
|
| Inpatients | 3 | 2022 | 135 | 0.790 |
Why?
|
| Immunosuppressive Agents | 4 | 2016 | 124 | 0.760 |
Why?
|
| Hypoglycemia | 1 | 2020 | 12 | 0.720 |
Why?
|
| Hypoglycemic Agents | 1 | 2020 | 33 | 0.710 |
Why?
|
| Adult | 14 | 2022 | 7448 | 0.710 |
Why?
|
| Antifungal Agents | 2 | 2018 | 38 | 0.700 |
Why?
|
| Quality Indicators, Health Care | 1 | 2020 | 36 | 0.700 |
Why?
|
| Electronic Health Records | 1 | 2020 | 63 | 0.690 |
Why?
|
| Humans | 26 | 2023 | 26286 | 0.640 |
Why?
|
| Lung Transplantation | 2 | 2016 | 13 | 0.640 |
Why?
|
| Cryptococcosis | 1 | 2018 | 5 | 0.610 |
Why?
|
| Population Health | 1 | 2018 | 4 | 0.600 |
Why?
|
| Consensus | 1 | 2018 | 83 | 0.590 |
Why?
|
| Kidney Failure, Chronic | 2 | 2016 | 151 | 0.590 |
Why?
|
| Ustilaginales | 1 | 2017 | 1 | 0.570 |
Why?
|
| United States | 6 | 2022 | 1990 | 0.570 |
Why?
|
| Yeasts | 1 | 2017 | 3 | 0.570 |
Why?
|
| Dermatomycoses | 1 | 2017 | 2 | 0.570 |
Why?
|
| HIV Infections | 2 | 2022 | 460 | 0.570 |
Why?
|
| Fungemia | 1 | 2017 | 9 | 0.560 |
Why?
|
| Exanthema | 1 | 2017 | 12 | 0.560 |
Why?
|
| Staphylococcus lugdunensis | 1 | 2016 | 1 | 0.560 |
Why?
|
| Endocarditis, Bacterial | 1 | 2016 | 5 | 0.550 |
Why?
|
| Risk Factors | 7 | 2022 | 2265 | 0.550 |
Why?
|
| Roseolovirus Infections | 1 | 2016 | 4 | 0.550 |
Why?
|
| Middle Aged | 12 | 2020 | 8601 | 0.530 |
Why?
|
| Bacteremia | 1 | 2016 | 97 | 0.520 |
Why?
|
| Liver Failure | 1 | 2015 | 8 | 0.500 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 13 | 0.480 |
Why?
|
| Heart Transplantation | 1 | 2014 | 24 | 0.480 |
Why?
|
| International Classification of Diseases | 1 | 2014 | 12 | 0.470 |
Why?
|
| Liver Transplantation | 1 | 2015 | 65 | 0.460 |
Why?
|
| Male | 14 | 2020 | 14162 | 0.450 |
Why?
|
| Anti-Bacterial Agents | 3 | 2022 | 339 | 0.450 |
Why?
|
| Pneumonia, Viral | 1 | 2015 | 87 | 0.440 |
Why?
|
| Aged | 8 | 2022 | 8765 | 0.420 |
Why?
|
| Immunocompromised Host | 3 | 2017 | 43 | 0.400 |
Why?
|
| Time Factors | 5 | 2016 | 1391 | 0.390 |
Why?
|
| Lemierre Syndrome | 1 | 2011 | 1 | 0.380 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 326 | 0.370 |
Why?
|
| Incidence | 3 | 2021 | 716 | 0.360 |
Why?
|
| Young Adult | 5 | 2018 | 1886 | 0.350 |
Why?
|
| Ganciclovir | 2 | 2022 | 8 | 0.340 |
Why?
|
| Hospital Mortality | 3 | 2015 | 136 | 0.340 |
Why?
|
| Multivariate Analysis | 3 | 2015 | 305 | 0.340 |
Why?
|
| Postoperative Complications | 1 | 2016 | 869 | 0.340 |
Why?
|
| Female | 11 | 2018 | 14539 | 0.330 |
Why?
|
| Directly Observed Therapy | 1 | 2006 | 2 | 0.280 |
Why?
|
| Graft Survival | 2 | 2017 | 90 | 0.270 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2006 | 62 | 0.270 |
Why?
|
| HIV Seropositivity | 1 | 2006 | 50 | 0.270 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 145 | 0.240 |
Why?
|
| Comorbidity | 2 | 2014 | 475 | 0.210 |
Why?
|
| Linezolid | 1 | 2022 | 3 | 0.210 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2022 | 73 | 0.210 |
Why?
|
| Carbapenems | 1 | 2022 | 32 | 0.210 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2022 | 43 | 0.200 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2022 | 48 | 0.200 |
Why?
|
| Benchmarking | 1 | 2022 | 35 | 0.200 |
Why?
|
| Virus Diseases | 1 | 2022 | 9 | 0.200 |
Why?
|
| Vancomycin | 1 | 2022 | 52 | 0.200 |
Why?
|
| Follow-Up Studies | 3 | 2016 | 1738 | 0.200 |
Why?
|
| Pancreas Transplantation | 1 | 2021 | 16 | 0.200 |
Why?
|
| Medicare | 1 | 2022 | 114 | 0.190 |
Why?
|
| Pancreas | 1 | 2021 | 28 | 0.190 |
Why?
|
| Rectal Prolapse | 1 | 2021 | 1 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 51 | 0.190 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 21 | 0.180 |
Why?
|
| Adolescent | 2 | 2018 | 2080 | 0.180 |
Why?
|
| Cohort Studies | 2 | 2016 | 1838 | 0.180 |
Why?
|
| HIV-1 | 1 | 2022 | 223 | 0.180 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 63 | 0.180 |
Why?
|
| Insulin | 1 | 2020 | 76 | 0.170 |
Why?
|
| Kidney | 1 | 2021 | 156 | 0.170 |
Why?
|
| Biomarkers | 1 | 2022 | 556 | 0.170 |
Why?
|
| Laparoscopy | 1 | 2021 | 160 | 0.160 |
Why?
|
| Meningitis, Cryptococcal | 1 | 2018 | 2 | 0.150 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 4675 | 0.150 |
Why?
|
| Urinary Tract Infections | 1 | 2017 | 29 | 0.140 |
Why?
|
| Saccharomyces | 1 | 2017 | 1 | 0.140 |
Why?
|
| Idarubicin | 1 | 2017 | 1 | 0.140 |
Why?
|
| Echinocandins | 1 | 2017 | 3 | 0.140 |
Why?
|
| Cryptococcus | 1 | 2017 | 2 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2017 | 6 | 0.140 |
Why?
|
| Amphotericin B | 1 | 2017 | 5 | 0.140 |
Why?
|
| Trichosporon | 1 | 2017 | 2 | 0.140 |
Why?
|
| Cytarabine | 1 | 2017 | 11 | 0.140 |
Why?
|
| Vidarabine | 1 | 2017 | 9 | 0.140 |
Why?
|
| Lipopeptides | 1 | 2017 | 10 | 0.140 |
Why?
|
| Voriconazole | 1 | 2017 | 11 | 0.140 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2017 | 8 | 0.140 |
Why?
|
| Salvage Therapy | 1 | 2017 | 36 | 0.140 |
Why?
|
| Fever | 1 | 2017 | 35 | 0.140 |
Why?
|
| Paecilomyces | 1 | 2016 | 2 | 0.140 |
Why?
|
| Herpesvirus 7, Human | 1 | 2016 | 2 | 0.140 |
Why?
|
| Herpesvirus 6, Human | 1 | 2016 | 3 | 0.140 |
Why?
|
| Lung Diseases, Fungal | 1 | 2016 | 10 | 0.140 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2016 | 6 | 0.130 |
Why?
|
| Biopsy | 1 | 2017 | 200 | 0.130 |
Why?
|
| Dyspnea | 1 | 2016 | 39 | 0.130 |
Why?
|
| Pharmacoepidemiology | 1 | 2016 | 4 | 0.130 |
Why?
|
| Medicare Part D | 1 | 2016 | 7 | 0.130 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 22 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 51 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 112 | 0.130 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 224 | 0.120 |
Why?
|
| California | 1 | 2014 | 27 | 0.120 |
Why?
|
| Florida | 1 | 2014 | 21 | 0.120 |
Why?
|
| Income | 1 | 2014 | 72 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2015 | 333 | 0.110 |
Why?
|
| Treatment Outcome | 3 | 2021 | 3391 | 0.110 |
Why?
|
| Prognosis | 1 | 2016 | 758 | 0.110 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 936 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2014 | 209 | 0.100 |
Why?
|
| Age Factors | 1 | 2014 | 753 | 0.100 |
Why?
|
| Bacterial Typing Techniques | 1 | 2011 | 10 | 0.090 |
Why?
|
| Molecular Typing | 1 | 2011 | 8 | 0.090 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 2011 | 9 | 0.090 |
Why?
|
| Genotype | 1 | 2011 | 335 | 0.090 |
Why?
|
| Cerebral Infarction | 1 | 2011 | 150 | 0.090 |
Why?
|
| Astacoidea | 1 | 2009 | 1 | 0.090 |
Why?
|
| Lung Diseases, Parasitic | 1 | 2009 | 1 | 0.090 |
Why?
|
| Paragonimiasis | 1 | 2009 | 1 | 0.090 |
Why?
|
| Paragonimus westermani | 1 | 2009 | 1 | 0.090 |
Why?
|
| Shellfish | 1 | 2009 | 2 | 0.090 |
Why?
|
| Urban Health | 1 | 2006 | 22 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2006 | 92 | 0.060 |
Why?
|
| Patient Compliance | 1 | 2006 | 145 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2006 | 378 | 0.060 |
Why?
|
| Hospitalization | 1 | 2006 | 294 | 0.060 |
Why?
|
| Health Facilities | 1 | 2023 | 19 | 0.050 |
Why?
|
| Patients | 1 | 2023 | 31 | 0.050 |
Why?
|
| Proviruses | 1 | 2022 | 3 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 16 | 0.050 |
Why?
|
| Virus Latency | 1 | 2022 | 15 | 0.050 |
Why?
|
| Tissue Donors | 1 | 2021 | 72 | 0.050 |
Why?
|
| Hospitals | 1 | 2022 | 150 | 0.050 |
Why?
|
| Perineum | 1 | 2021 | 7 | 0.050 |
Why?
|
| Infection Control | 1 | 2022 | 163 | 0.050 |
Why?
|
| Pandemics | 1 | 2022 | 238 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 147 | 0.040 |
Why?
|
| Microbiological Techniques | 1 | 2016 | 5 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2016 | 22 | 0.030 |
Why?
|
| Microscopy | 1 | 2016 | 10 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2016 | 28 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 314 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 322 | 0.030 |
Why?
|
| Midwestern United States | 1 | 2016 | 62 | 0.030 |
Why?
|
| Risk | 1 | 2016 | 199 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2016 | 723 | 0.030 |
Why?
|
| Food Parasitology | 1 | 2009 | 1 | 0.020 |
Why?
|
| Food Contamination | 1 | 2009 | 3 | 0.020 |
Why?
|
| Praziquantel | 1 | 2009 | 4 | 0.020 |
Why?
|
| Hemoptysis | 1 | 2009 | 7 | 0.020 |
Why?
|
| Anthelmintics | 1 | 2009 | 8 | 0.020 |
Why?
|
| Missouri | 1 | 2009 | 27 | 0.020 |
Why?
|
| Tuberculosis | 1 | 2009 | 19 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 347 | 0.020 |
Why?
|
| Animals | 1 | 2009 | 3538 | 0.010 |
Why?
|